In breast cancer cells, gefitinib has been reported to reduce Forkhead Box M1 (FoxM1) levels through the activation of FoxO3a, that in turn results in inhibition of cyclin B, CDC25B and cell death [78,87]. The gene discussed is FOXM1; the disease is breast cancer.